Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

15.59USD
11:35am EDT
Change (% chg)

$-0.01 (-0.06%)
Prev Close
$15.60
Open
$15.58
Day's High
$15.65
Day's Low
$15.38
Volume
98,943
Avg. Vol
779,293
52-wk High
$17.60
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Sees FY 2018 Revenue $75 Million To $85 Million
Wednesday, 28 Feb 2018 07:00am EST 

Feb 28 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND 2018 CORPORATE UPDATES.SEES FY 2018 REVENUE $75 MILLION TO $85 MILLION.DEVELOP AND EXPAND PRECLINICAL PIPELINE TO ENSURE AT LEAST ONE NEW CLINICAL PROGRAM IN 2019.ON TRACK TO ACHIEVE FY18 REVENUE GUIDANCE OF $75M-$85M.REITERATED FULL-YEAR 2018 REVENUE AND NET CASH SPEND GUIDANCE.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $358.6 MILLION AT DECEMBER 31, 2017.FY2018 REVENUE VIEW $86.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Announces Closing Of Underwritten Offering Of Common Stock
Wednesday, 21 Feb 2018 04:30pm EST 

Feb 21 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN OFFERING OF COMMON STOCK.  Full Article

Amicus Therapeutics Prices Underwritten Offering Of Common Stock
Thursday, 15 Feb 2018 07:00pm EST 

Feb 15 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK.SAYS OFFERING OF 19.4 MILLION COMMON SHARES PRICED AT $15.50PER SHARE.  Full Article

Amicus Therapeutics Announces Public Offering Of Common Stock
Wednesday, 14 Feb 2018 04:01pm EST 

Feb 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS INC - COMMENCED A $250 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.AMICUS THERAPEUTICS INC - EXPECTS TO USE NET PROCEEDS OF OFFERING FOR INVESTMENT IN U.S., INTERNATIONAL COMMERCIAL INFRASTRUCTURE FOR MIGALASTAT HCL.AMICUS THERAPEUTICS INC - TO ALSO USE NET PROCEEDS OF OFFERING FOR INVESTMENT IN MANUFACTURING CAPABILITIES FOR ATB200, AMONG OTHERS.  Full Article

U.S. FDA Files NDA Under Priority Review For Migalastat
Monday, 12 Feb 2018 07:30am EST 

Feb 12 (Reuters) - Amicus Therapeutics Inc ::U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018.  Full Article

Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS SEES GALAFOLD FY 2018 REVENUE $75 MILLION TO $85 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED ABOUT $359 MILLION AT DEC 31, 2017.EXPECTS FULL-YEAR 2018 NET CASH SPEND OF BETWEEN $230 MILLION AND $260 MILLION.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST SECOND HALF OF 2019.FY2018 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article

Amicus Therapeutics Q3 loss per share $0.69
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Amicus Therapeutics Inc ::Amicus therapeutics announces third quarter 2017 financial results and corporate updates.Q3 loss per share $0.69.Q3 revenue $10.9 million versus I/B/E/S view $9.5 million.Q3 adjusted loss per share $0.41 excluding items.Q3 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.Amicus Therapeutics Inc - ‍reiterated full-year 2017 financial guidance​.Amicus Therapeutics Inc - ‍current cash position anticipated to fund ongoing operations into at least H2 2019​.  Full Article

Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society
Wednesday, 4 Oct 2017 06:00am EDT 

Oct 4 (Reuters) - Amicus Therapeutics Inc : :Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society.Amicus Therapeutics Inc - ‍pulmonary function generally improved or remained stable at 6 and 9 months​.Amicus Therapeutics - plans to continue collaborative discussions with regulators in US and EU, expects to provide update in first half of 2018.  Full Article

Amicus Therapeutics says U.S. FDA granted orphan drug designation to ATB200/AT2221 for Pompe disease
Thursday, 21 Sep 2017 07:30am EDT 

Sept 21 (Reuters) - Amicus Therapeutics Inc :Says ‍U.S. FDA has granted orphan drug designation to ATB200/AT2221​ for Pompe disease​.Amicus Therapeutics - ‍look forward to announcing new clinical data in all patients from ATB200/AT2221​ study at World Muscle Society in early Oct.  Full Article

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES